Clinical trial
RESPIRARE - A Phase 2, Randomized, Double-blinded, Placebo-controlled, Efficacy and Safety Study of Cudetaxestat (BLD-0409) Assessed Across Three Dose Ranges With or Without Standard of Care (Nintedanib or Pirfenidone) in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT05373914 is registered in ClinicalTrials.gov with Blade Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- RESPIRARE - A Phase 2, Randomized, Double-blinded, Placebo-controlled, Efficacy and Safety Study of Cudetaxestat (BLD-0409) Assessed Across Three Dose Ranges With or Without Standard of Care (Nintedanib or Pirfenidone) in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Lead sponsor
- Blade Therapeutics
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- May 31, 2022
- Completion date
- March 31, 2024
- Enrollment
- 200 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.